Related Experiment Video
Updated: Dec 18, 2025
06:47
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
Published on: September 27, 2017
10.0K
New and Emerging Systemic Treatments for Atopic Dermatitis
Megan Newsom1, Arjun M Bashyam2, Esther A Balogh2
1Department of Dermatology, Center for Dermatology Research, Medical Center Boulevard, Wake Forest School of Medicine, Winston-Salem, North Carolina, 27157-1071, USA. mnewsom@wakehealth.edu.
Drugs
|June 11, 2020
Summary
New biologic therapies targeting specific pathways like IL-13 and JAK inhibitors offer promising alternatives for atopic dermatitis (AD). Clinical trial data for these novel treatments are reviewed, comparing their potential safety and efficacy.
Area of Science:
- Immunodermatology
- Molecular biology
Background:
- Atopic dermatitis (AD) is a common inflammatory skin disease with significant morbidity.
- Current treatments like corticosteroids and immunosuppressants have limitations and side effects.
- Understanding AD pathogenesis has driven the development of targeted therapies.
Purpose of the Study:
- To review novel targeted treatments for atopic dermatitis.
- To discuss the role of specific molecular targets (IL-13, IL-31, OX40, JAK kinases) in AD.
- To analyze Phase II and III clinical trial data for emerging AD therapies.
Main Methods:
- Systematic review of published Phase II and III clinical trial data.
- Analysis of therapeutic targets including interleukins, OX40, and Janus kinase (JAK) family proteins.
- Evaluation of specific agents: dupilumab, tralokinumab, lebrikizumab, nemolizumab, anti-OX40 antibody, baricitinib, abrocitinib, and upadacitinib.
Main Results:
- Several novel agents targeting IL-13, IL-31, OX40, and JAK pathways are in late-stage development.
- Published data for dupilumab, tralokinumab, lebrikizumab, nemolizumab, anti-OX40 antibody, baricitinib, abrocitinib, and upadacitinib show potential efficacy.
- Comparison between narrow-acting (e.g., single interleukin inhibitors) and broad-acting (e.g., JAK inhibitors) agents is ongoing.
Conclusions:
- Novel targeted therapies represent a significant advancement in atopic dermatitis treatment.
- These new agents offer potential alternatives to traditional treatments with improved safety profiles.
- Further research is needed to establish the comparative efficacy and safety of different classes of novel agents.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.6K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.6K
01:20Asthma: Pathogenesis and Management
1.1K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.1K
01:19Antiasthma Drugs: Leukotriene Modifiers
1.6K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.6K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.4K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.4K
01:30Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
355
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
355